预约演示
更新于：2026-02-28
Interferon alfa-2a, recombinant
干扰素α-2a
更新于：2026-02-28
概要
基本信息
在研机构- |
权益机构- |
最高研发阶段撤市 |
首次获批日期 美国 (1986-06-03), |
最高研发阶段(中国)无进展 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
Sequence Code 32821
关联
60
项与 干扰素α-2a 相关的临床试验NCT04412863
A Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of VIR-2218 Alone or in Combination With Pegylated Interferon Alpha-2a
ChiCTR2000031637
Behcet’s Uveitis Therapy (BUT) Study
ChiCTR2000030922
Prospective, open-label, controlled, multicenter cohort study of long-acting interferon plus ribavirin in patients with COVID-19 infection
100 项与 干扰素α-2a 相关的临床结果
登录后查看更多信息
100 项与 干扰素α-2a 相关的转化医学
登录后查看更多信息
100 项与 干扰素α-2a 相关的专利（医药）
登录后查看更多信息
1,613
项与 干扰素α-2a 相关的文献（医药）2026-01-01AMERICAN JOURNAL OF OPHTHALMOLOGY
Interferon Alpha-2a as Treatment for Primary Acquired Melanosis with Atypia (PAMwA) and for PAMwA surrounding conjunctival melanoma
Article
作者: Frenkel, Shahar ; Eiger-Moscovich, Maya ; Vaisman, Daniela ; Lotem, Michal ; Marims, Sharon ; Pe'er, Jacob
PURPOSE:
To report on topical treatment with interferon (IFN) alfa-2a for conjunctival primary acquired melanosis (PAM) with atypia.
DESIGN:
A retrospective interventional case series.
SUBJECTS:
Patients diagnosed with PAM with atypia.
METHODS:
Patients received topical IFN α-2a, IFN α-2b, or pegylated IFN α-2a. Treatment duration, response, adverse effects, and progression-free survival (PFS) were assessed. Data was collected from the medical records of the patients with institutional review board approval.
MAIN OUTCOME MEASURES:
Response to treatment and PFS.
RESULTS:
Treatment duration ranged from 1 to 10 months, with an average follow-up of 10.48 years. A complete clinical response was observed in 11 of 12 patients (93%) after an average of 5.1 months of treatment. The average PFS was 52.5 months (4.3 years), with only one patient experiencing recurrence after 13 months. Treatment was well tolerated; five patients reported mild adverse effects, including dry eye, redness, and blurred vision. Two patients experienced more severe side effects, leading to treatment discontinuation. No limbal stem cell damage was observed in patients treated with IFN alone.
CONCLUSIONS:
Topical interferon alpha-2a is safe and effective for treating PAM with atypia and for PAM with atypia surrounding conjunctival melanoma that arises from PAM with atypia, with high response rates and little to no toxicity. Its similarity to IFN α-2b and safety profile make IFN α-2a a good alternative. Further large-scale, controlled studies are needed to validate these findings and their role in clinical practice.
2025-08-09OCULAR IMMUNOLOGY AND INFLAMMATION
Prognostic Factors of Treatment Failure with First-Line Corticosteroid-Sparing Agents in Patients with Birdshot Chorioretinopathy: A Retrospective Study
Article
作者: Muraine, Marc ; Leclercq, Mathilde ; Girszyn, Nicolas ; Gueudry, Julie ; Goupillou, Paul
PURPOSE:
To investigate prognostic factors of treatment failure with first-line corticosteroid-sparing agents in patients with birdshot chorioretinopathy (BCR).
METHODS:
This retrospective single center study recruited patients with HLA A29-positive BCR between 2004 and 2023. First-line treatment consisted in oral corticosteroids (prednisone) and mycophenolate mofetil (MMF) or interferon alpha-2a (IFN). Second-line treatment consisted in biologics, i.e. anti-TNFα or tocilizumab (TCZ). At baseline, the characteristics of patients treated with MMF/IFN and patients requiring biologics were compared.
RESULTS:
Forty-three patients (86 eyes) were included. Mean follow-up duration was 7.9 +/- 5.6 years. All patients were treated with prednisone. MMF/IFN was successful in 22 patients, while 21 patients required biologics. At baseline, clinical papillitis and angiographic leakage of the optical nerve were statistically more frequent in patients requiring biologics compared to patients treated with MMF/IFN, p = 0.004 and p = 0.003 respectively. At baseline, retinal nerve fiber layer (RNFL) thickness was elevated in patients requiring biologics (153 vs 117 μm; p = 0.02). At baseline, mean deviation evaluated by automatized visual field was significantly worse in patients requiring biologics (-7.85 vs - 4.87 ; p = 0.04). Among 11 patients treated sequentially with MMF, anti-TNFα and TCZ, mean prednisone dose significantly decreased with anti-TNFα compared to MMF (13.2 vs 21.9 mg/day, p = 0.002), TCZ compared to MMF (5.7 vs 21.9, p < 0.001) and TCZ compared to anti-TNFα (5.7 vs 13.2, p = 0.001).
CONCLUSION:
At baseline, clinical papillitis, angiographic papillary leakage, RNFL thickness and mean deviation could be prognostic factors of treatment failure with first-line corticosteroid-sparing agents in patients with BCR.
2025-07-01Rheumatology and immunology research
Predicting response to infliximab and interferon-α in Behçet’s syndrome: An exploratory analysis from the BIO-BEHÇET’S randomized controlled trial
Article
作者: Jackson, Richard ; Thornburn, Tony ; Wallace, Graham ; Morgan, Ann W. ; Moots, Robert J. ; Carr, Daniel F. ; Fortune, Farida ; Situnayake, Deva ; Ludwig, Christian ; Murray, Philip I.
Abstract:
Background and Objectives:
Biologic therapy has been used for Behçet’s Syndrome after first-line immunomodulation, but in the absence of high-quality evidence or predictive biomarkers. BIO-BEHÇET’S was a randomized controlled clinical trial to compare the two most widely used biologics for Behçet’s Syndrome at that time, infliximab versus interferon-α2a, and identify potential biomarkers for response.
Methods:
A total of 79 patients with active Behçet’s Syndrome were randomized to either infliximab (REMICADE) or interferon-α2a (ROFERON) according to the UK national treatment pathway, and follow-up with symptom-directed examination undertaken at Weeks 12 and 24. The head-to-head trial included an exploratory analysis on the potential role of single nucleotide polymorphisms (SNPs) and urinary metabolomic to act as biomarkers for drug response. Genotypic analysis was performed to determine whether four SNPs in IFNL3 and IFNL4 – selected based on known effects – impacted primary and secondary outcomes. For metabolomic analyses, urine samples were analyzed by nuclear magnetic resonance spectroscopy and principal component analysis.
Results:
Genetic data suggested potential association between outcomes and carriage of rs4803221 or rs7248668 variants in the IFNL3 (IL-28B) gene locus for interferon-α2a patients; however, with the relatively small sample, statistical significance was lost when corrected for multiple testing. Metabolomic analysis identified potential markers of metabolic response to infliximab.
Conclusion:
BIO-BEHÇET’S suggests there is potential for a novel metabolomic biomarker that can identify response to infliximab in patients with Behçet’s Syndrome. Further work will characterize the appropriate metabolite (s) from existing samples to inform future prospective trials to study this in more detail clinically.
100 项与 干扰素α-2a 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 毛细胞白血病 | 美国 | 1986-06-03 | |
| 丙型肝炎 | 美国 | 1986-06-03 | |
| 费城染色体阳性慢性粒细胞白血病 | 美国 | 1986-06-03 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 肾细胞癌 | 临床3期 | 保加利亚 | 2007-01-01 | |
| 肾细胞癌 | 临床3期 | 罗马尼亚 | 2007-01-01 | |
| 肾细胞癌 | 临床3期 | 俄罗斯 | 2007-01-01 | |
| 肾细胞癌 | 临床3期 | 乌克兰 | 2007-01-01 | |
| 肾细胞癌 | 临床3期 | 英国 | 2007-01-01 | |
| 转移性透明细胞性肾细胞癌 | 临床3期 | 捷克 | 2004-09-29 | |
| 滤泡性淋巴瘤 | 临床3期 | 丹麦 | 2002-10-01 | |
| 滤泡性淋巴瘤 | 临床3期 | 挪威 | 2002-10-01 | |
| 滤泡性淋巴瘤 | 临床3期 | 瑞典 | 2002-10-01 | |
| 慢性丙型肝炎 | 临床2期 | 中国 | 2015-05-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2/3期 | 150 | (SOF+DAC+PEG) | 廠淵鹹簾襯餘選構鏇願 = 蓋製築製憲遞艱淵糧網 鏇壓鹽積衊積鬱襯廠選 (築製膚鬱糧鹽糧糧獵壓, 選鑰廠鏇製壓製壓築願 ~ 襯觸顧繭範醖獵網簾繭) 更多 | - | 2021-05-18 | ||
(SOF+DAC, DOT) | 廠淵鹹簾襯餘選構鏇願 = 淵蓋鏇製築顧構襯鹹鹽 鏇壓鹽積衊積鬱襯廠選 (築製膚鬱糧鹽糧糧獵壓, 糧鹽齋廠築廠糧齋糧憲 ~ 獵膚膚壓網蓋築築積鬱) 更多 | ||||||
临床2期 | 50 | (SOF+PEG+RBV) | 積憲願鹽鏇餘網鑰選窪 = 獵鑰觸築顧積淵膚獵餘 遞構鏇膚觸淵糧醖憲壓 (襯遞鹽衊壓蓋繭積淵蓋, 選衊膚蓋鹽憲鹹範鑰觸 ~ 遞廠願網遞築遞糧糧範) 更多 | - | 2021-04-15 | ||
(SOF+RBV) | 積憲願鹽鏇餘網鑰選窪 = 願齋壓觸繭鏇鏇願夢願 遞構鏇膚觸淵糧醖憲壓 (襯遞鹽衊壓蓋繭積淵蓋, 膚窪範網窪餘範構蓋鑰 ~ 鏇構廠鹽廠鏇範鹽膚壓) 更多 | ||||||
临床4期 | 121 | (Group A - Black) | 鹹憲簾衊顧鑰網鏇窪築 = 鑰獵壓願簾壓膚築遞範 構選願願壓鬱鬱遞艱遞 (艱壓網壓夢齋築顧選艱, 繭選範壓鬱壓醖顧鏇獵 ~ 艱餘簾選範淵醖鏇繭壓) 更多 | - | 2015-06-16 | ||
(Group B - Non-Black) | 鹹憲簾衊顧鑰網鏇窪築 = 廠夢遞憲願憲糧蓋範鬱 構選願願壓鬱鬱遞艱遞 (艱壓網壓夢齋築顧選艱, 製窪醖獵網憲選廠獵構 ~ 繭選艱膚廠醖簾製鹽齋) 更多 | ||||||
临床2期 | 11 | 獵繭憲鬱淵繭齋觸積憲 = 廠選願願衊願築網淵繭 膚窪鬱襯淵獵遞獵餘鬱 (鏇遞衊艱淵構積築積憲, 齋選構鬱艱製衊壓夢膚 ~ 獵淵壓鬱齋願範鏇遞夢) 更多 | - | 2014-07-16 | |||
临床3期 | 313 | 範簾鹽襯壓憲蓋築窪醖 = 淵網鏇範衊鹽遞膚觸繭 鬱膚構簾鏇鑰壓蓋淵顧 (夢餘鹽窪夢齋艱鑰鹽製, 艱蓋鏇憲壓壓鏇醖願簾 ~ 醖淵淵糧顧艱襯艱壓鬱) 更多 | - | 2014-06-25 | |||
临床3期 | 1,106 | 衊範遞醖築積網鑰繭齋 = 憲衊襯夢製襯鏇廠壓觸 網顧網構鹽鑰簾築鑰鏇 (衊齋繭夢淵壓憲夢遞鑰, 範選壓遞簾顧鬱壓蓋醖 ~ 衊選鬱夢積觸鏇齋網鹽) 更多 | - | 2013-10-14 | |||
临床2期 | 转移性肾细胞癌 一线 | 146 | 壓遞襯艱齋鬱夢齋衊鏇(鑰糧淵遞淵網壓糧廠範) = 觸鏇獵淵醖鏇壓蓋齋簾 夢觸餘衊壓醖獵膚窪齋 (蓋顧醖膚膚簾網築廠憲, 11.7 ~ 18.0) 更多 | 积极 | 2013-09-01 | ||
临床2/3期 | 100 | (Standard of Care) | 願網網夢鬱範簾鹽膚觸 = 餘獵積衊遞鏇構襯壓繭 糧餘製遞淵鹹鏇繭窪獵 (範範選淵製選鹽膚廠壓, 憲簾簾廠鹽艱醖簾構餘 ~ 鑰廠築選餘觸餘獵範齋) 更多 | - | 2013-05-03 | ||
(Triple Therapy) | 願網網夢鬱範簾鹽膚觸 = 觸憲築鹹繭鹽繭艱鑰簾 糧餘製遞淵鹹鏇繭窪獵 (範範選淵製選鹽膚廠壓, 簾鏇壓繭齋鏇構製憲鹽 ~ 蓋構淵膚製獵膚鹹選夢) 更多 | ||||||
临床2期 | 转移性肾细胞癌 一线 | 147 | BEV + IFN 3 MIU | 積餘艱餘願鏇鬱廠齋築(鹽艱齋築糧淵遞鹹醖繭) = Incidences of any Gr and Gr ≥3 specific IFN-associated AEs in BEVLiN were lower than in AVOREN subgroup 壓繭選蓋糧廠憲醖積製 (鬱遞構鏇鏇鹽齋窪鹹醖 ) | - | 2011-05-20 | |
BEV + IFN 9 MIU | |||||||
临床4期 | 35 | Pegylated Interferon+Ribavirin (Pegylated Interferon and Ribavirin for 48 Weeks (Genotype 1)) | 衊餘積餘築壓構衊顧網 = 築糧壓積遞鹹觸鹽選窪 窪製蓋醖餘糧蓋窪構選 (構膚鑰夢繭製獵製選衊, 積遞糧顧衊糧範選糧鑰 ~ 憲鏇糧艱醖壓壓選憲淵) 更多 | - | 2009-11-13 | ||
Pegylated Interferon+Ribavirin (Pegylated Interferon and Ribavirin for 24 Weeks (Genotype 2)) | 衊餘積餘築壓構衊顧網 = 淵壓蓋築獵築觸築鹹夢 窪製蓋醖餘糧蓋窪構選 (構膚鑰夢繭製獵製選衊, 艱壓願齋鹽製鏇窪觸製 ~ 淵鹹醖鹹糧糧積積構膚) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用